Unknown

Dataset Information

0

Development of a cancer-marker activated enzymatic switch from the herpes simplex virus thymidine kinase.


ABSTRACT: Discovery of new cancer biomarkers and advances in targeted gene delivery mechanisms have made gene-directed enzyme prodrug therapy (GDEPT) an attractive method for treating cancer. Recent focus has been placed on increasing target specificity of gene delivery systems and reducing toxicity in non-cancer cells in order to make GDEPT viable. To help address this challenge, we have developed an enzymatic switch that confers higher prodrug toxicity in the presence of a cancer marker. The enzymatic switch was derived from the herpes simplex virus thymidine kinase (HSV-TK) fused to the CH1 domain of the p300 protein. The CH1 domain binds to the C-terminal transactivation domain (C-TAD) of the cancer marker hypoxia inducible factor 1?. The switch was developed using a directed evolution approach that evaluated a large library of HSV-TK/CH1 fusions using a negative selection for azidothymidine (AZT) toxicity and a positive selection for dT phosphorylation. The identified switch, dubbed TICKLE (Trigger-Induced Cell-Killing Lethal-Enzyme), confers a 4-fold increase in AZT toxicity in the presence of C-TAD. The broad substrate specificity exhibited by HSV-TK makes TICKLE an appealing prospect for testing in medical imaging and cancer therapy, while establishing a foundation for further engineering of nucleoside kinase protein switches.

SUBMITTER: Shelat NY 

PROVIDER: S-EPMC6080848 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Development of a cancer-marker activated enzymatic switch from the herpes simplex virus thymidine kinase.

Shelat Nirav Y NY   Parhi Sidhartha S   Ostermeier Marc M  

Protein engineering, design & selection : PEDS 20161215 2


Discovery of new cancer biomarkers and advances in targeted gene delivery mechanisms have made gene-directed enzyme prodrug therapy (GDEPT) an attractive method for treating cancer. Recent focus has been placed on increasing target specificity of gene delivery systems and reducing toxicity in non-cancer cells in order to make GDEPT viable. To help address this challenge, we have developed an enzymatic switch that confers higher prodrug toxicity in the presence of a cancer marker. The enzymatic s  ...[more]

Similar Datasets

| S-EPMC5890518 | biostudies-literature
| S-EPMC7016767 | biostudies-literature
| S-EPMC10783082 | biostudies-literature
| S-EPMC2727455 | biostudies-literature
| S-EPMC2570551 | biostudies-literature
| S-EPMC303395 | biostudies-literature
| S-EPMC6413063 | biostudies-literature
| S-EPMC1933309 | biostudies-literature
| S-EPMC7650665 | biostudies-literature
| S-EPMC3594035 | biostudies-literature